LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Meta Expands AI Training With Employee Activity Tracking Tools 
SAN DIEGO, March 29, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present at the 16th Annual Needham Healthcare Conference at 2:20 pm EDT on Wednesday, April 5, 2017, at the Westin Grand Central Hotel in New York, NY.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
